329216-67-3 Usage
Description
Quetiapine Hydroxy Impurity is a chemical compound that is formed as a byproduct during the synthesis of the antipsychotic drug Quetiapine. It is characterized by the presence of a hydroxyl group, which distinguishes it from the main Quetiapine molecule.
Uses
Used in Pharmaceutical Industry:
Quetiapine Hydroxy Impurity is used as a reference standard for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity and potency of the final drug product, as well as the consistency of the manufacturing process.
Used in Research and Development:
Quetiapine Hydroxy Impurity is utilized in research and development for the study of its chemical properties, potential side effects, and interactions with other compounds. This information can be valuable in optimizing the drug's formulation and understanding its mechanism of action.
Used in Drug Metabolism Studies:
As a metabolite of Quetiapine, Quetiapine Hydroxy Impurity is used in drug metabolism studies to investigate how the drug is processed and eliminated from the body. This can provide insights into the drug's safety profile and potential drug-drug interactions.
Used in Impurity Profiling:
Quetiapine Hydroxy Impurity is used in impurity profiling to assess the presence and levels of impurities in the drug product. This is important for regulatory compliance and ensuring the safety and efficacy of the drug.
Check Digit Verification of cas no
The CAS Registry Mumber 329216-67-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,9,2,1 and 6 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 329216-67:
(8*3)+(7*2)+(6*9)+(5*2)+(4*1)+(3*6)+(2*6)+(1*7)=143
143 % 10 = 3
So 329216-67-3 is a valid CAS Registry Number.
329216-67-3Relevant articles and documents
DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS
-
Page/Page column 26-27, (2010/04/23)
The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.
